共查询到20条相似文献,搜索用时 46 毫秒
1.
目的:探讨IL-2对CD4+CD25+调节性T细胞(Tregs)的增殖及功能的影响。方法:提取B6小鼠脾脏细胞,流式细胞仪分离CD4+CD25+Tregs,将新鲜分离的CD4+CD25+Tregs与抗CD3单克隆抗体、同种同系抗原递呈细胞(APCs)及外源性IL-2共同培养,测定其增殖活性;并检测体外扩增后的CD4+CD25+Tregs的免疫抑制活性及其Foxp3的表达。结果:与外源性IL-2共同培养的CD4+CD25+Tregs增殖程度强烈,与对照组比较,差异有统计学意义(P〈0.05);体外扩增的CD4+CD25+Tregs抑制CD4+CD25-T细胞增殖活性的能力与新鲜分离的CD4+CD25+Tregs相似(P〉0.05)。体外扩增的CD4+CD25+Tregs的Foxp3表达与新鲜分离的CD4+CD25+Tregs亦相似(P〉0.05)。结论:外源性IL-2能够消除CD4+CD25+Tregs的无反应状态,且体外扩增的CD4+CD25+Tregs保持了其抑制活性。 相似文献
2.
目的:观察白细胞介素-37(IL-37)在健康人外周血 CD4+CD25+调节性 T细胞(Treg)中的表达情况。方法:采用免疫磁性分离法分离人外周血 CD4+CD25+Treg,流式细胞技术分析其分离纯度,观察刺激剂组(每1×105个 CD4+CD25+Treg细胞加入20μl Dynabeads(R) Human Treg Expander)、非刺激剂组、空白对照组(单纯10%FCS-RPMI 1640培养)CD4+CD25+Treg细胞增殖活性及其差异。分别采用 Western blot和免疫荧光共聚焦技术检测 IL-37的表达水平与定位改变。结果:MACS分离人外周血 CD4+CD25+Treg 细胞纯度为93%,台盼蓝染色细胞活性为98%。与非刺激剂组和空白对照组相比,刺激剂组 CD4+CD25+Treg 增殖活性随时间延长而逐渐增加;非刺激剂组与空白对照组其增殖活性差异无显著性。Western blot 结果显示,正常CD4+CD25+Treg细胞表达 IL-37,在刺激剂作用下随作用时间延长 IL-37表达量增加。免疫荧光显微镜和免疫荧光共聚焦图像显示,刺激72 h后 IL-37在 CD4+CD25+Treg细胞内明显表达,并且在细胞质中表达丰富,近胞膜处表达密度较高。结论:IL-37在健康人外周血 CD4+CD25+Treg 细胞中表达,当受到有效刺激后 IL-37表达明显上升。 相似文献
3.
目的 探讨淋巴细胞主动免疫治疗对反复胚胎植入失败(RIF)患者外周血CD4+ CD25+调节性T淋巴细胞(CD4+CD25+Treg)表达的影响. 方法 选择在郑州大学第三附属医院生殖中心就诊的30例RIF患者(RIF组),采用荧光标记流式细胞分析技术,检测其淋巴主动免疫治疗前、后2周的外周血CD4+CD25+Treg表达,并选择同期正常未妊娠妇女20例作对照(对照组). 结果 (1)RIF组治疗前CD4+CD25+Treg占CD4+T细胞的比例显著低于对照组,差异有统计学意义(P<0.05);(2)RIF组治疗后CD4+CD25+Treg的表达率明显高于治疗前,差异有统计学意义(P<0.05). 结论 RIF的发生可能与CD4+CD25+Treg的表达下降有关;淋巴细胞主动免疫治疗可上调CD4+CD25+Treg的表达,调控母胎免疫耐受,有利于胚胎植入成功. 相似文献
4.
大鼠CD4^+CD25^+调节性T细胞的分离及功能鉴定 总被引:1,自引:0,他引:1
目的:研究利用免疫磁珠分选法稳定分离正常大鼠脾脏CD4^+CD25^+调节性T细胞的方法。方法:采用免疫磁珠两步法分离大鼠脾组织CD4^+CD25^+T细胞。首先采用藻红蛋白(PE)标记的抗CD25抗体和抗PE多功能磁珠试剂盒阳性分选CD25^+T细胞,再用抗异硫氰酸荧光素(FITC)标记抗体和抗IgG磁珠阳性分选获得CD4^+CD25^+T细胞。分离后的细胞经流式细胞仪检测分离纯度,台盼蓝染色检测细胞存活率,体外增殖实验检测其对CD4^+CD25^-T细胞的免疫抑制作用。结果:两次阳性分选后获得的CD4^+CD25^+T细胞纯度为(90.4±1.6)%,细胞存活率为(92.6±2.4)%。体外增殖实验表明,CD4^+CD25^+T细胞能明显抑制CD4^+CD25^-T细胞的增殖(P〈0.01)。结论:采用免疫磁珠法两次阳性分选,可稳定地获得纯度理想并有免疫抑制功能的大鼠CD4^+CD25^+T细胞。 相似文献
5.
CD4^+CD25^+调节性T细胞(Treg)在自身免疫耐受、免疫自稳、肿瘤免疫中发挥着重要作用,它可以抑制自身抗原或者非自身抗原如肿瘤抗原引起的免疫反应.人们对Treg细胞的免疫抑制作用已进行了相关的研究和临床应用,最新研究表明其能够诱导肿瘤特异性抗原和局部的免疫反应.此综述将讨论Treg细胞的相关表面分子及其在肿瘤免疫逃逸机制、肿瘤免疫治疗中的研究进展. 相似文献
6.
7.
目的 研究门静脉高压症(PHT)脾亢患者外周血CD4+CD25+CD127low/-调节性T细胞(Treg)与CD3+、CD4+、CD8+T细胞的表达变化.探讨脾脏免疫功能改变及其可能的调节机制.方法 PHT脾亢患者20例(脾亢组),健康成人18例(对照组),采用流式细胞术检测外周血中CD4+CD25+CD127low/-Treg及CD3+、CD4+、CD8+T细胞的表达变化.结果 脾亢组外周血中CD4+CD25+CD127low/-Treg占CD4+T细胞的比例为(5.3±3.0)%,明显高于对照组的(2.5±0.9)%(P<0.01).脾亢组CD3+、CD4+、CD8+T细胞含量均低于对照组(P<0.05).CD4+CD25+CD127low/-Treg的含量与CD3+T细胞比例呈负相关(r=-0.630,P<0.01),与CD4+T细胞比例呈负相关(r=-0.561,P<0.05).结论 PHT脾功能亢进患者CD4+CD25+CD127low/-调节性T细胞表达量增多,可能对脾脏免疫功能的调节有重要作用. 相似文献
8.
目的:探讨抗原特异性CD4+CD25+Treg细胞免疫对同种异体胰岛急性移植排斥反应的影响和机制。方法:用MACS分选供体抗原特异性CD4+CD25+Treg细胞免疫糖尿病BALB/cByJ受体小鼠,以ICR小鼠胰岛为供体行同种异体胰岛移植。观察移植后小鼠的存活时间、移植前后外周血CD4+和CD8+T细胞亚群的变化和移植物中Th1/Th2细胞因子mRNA表达水平的变化。结果:抗原特异性Treg细胞联合胰岛移植组(C组)胰岛移植物平均生存期为(34.57±17.15)d,显著长于单纯胰岛移植组(B组)的(10.6±1.82) d (P<0.01);移植后第3天,C组外周血CD4+/CD8+的值显著低于B组(P<0.01);C组移植物中IL-10,TGF-β mRNA表达比B组显著增强。B组移植物中IL-1β,IL-2及IFN-γ mRNA表达明显强于C组。结论:抗原特异性CD4+CD25+ Treg细胞可通过调节Th2/Th1之间的反应平衡而延长同种异体胰岛移植物的存活时间。 相似文献
9.
《中华实验外科杂志》2009,26(12)
目的 探讨应用流式细胞术检测肝癌患者外周血中CD4~+CD25~+调节性T细胞的变化及意义.方法 应用三色免疫荧光流式细胞仪测定37例肝癌患者及30例肝硬化患者外周血T细胞亚群CD4~+CD25~+/CD~+比值.采用酶联免疫吸附试验(ELISA)法检测外周血中转化生长因子β1(TGF-B1)的表达水平.结果 肝癌患者外周血CD4~+CD25~+/CD4~+比值较肝硬化患者显著增高,两者比较差异有统计学意义(P<0.05);肝癌患者外周血中CD4~+CD25~+T细胞水平与肝癌原发肿瘤的大小、TGF-βl呈正相关(P<0.05).结论 肝癌患者外周血中CD4~+CD25~+调节性T细胞增多,对肝癌患者具有免疫抑制作用. 相似文献
10.
目的:探讨胰腺癌患者外周血中高表达CD25的CD4+调节性T细胞(CD4+CD25high T)的表达比率及其临床意义。
方法:选取50例确诊胰腺癌患者作为胰腺癌组、50例急性胰腺炎患者作为AP组、50例健康体检对象作为对照组,分别采用流式细胞技术检测三组研究对象的外周血的CD4+CD25high T细胞水平,采用ELISA检测胰腺癌患者外周血γ-干扰素(INF-γ)、白细胞介素4(IL-4)、白细胞介素10(IL-10)的水平。
结果:胰腺癌组患者的CD4+CD25high T细胞占CD4+T细胞的比率显著的高于AP组、对照组(P<0.05),AP组的CD4+CD25high T细胞占CD4+T细胞的比率显著的高于对照组(P<0.05); I~II期患者CD4+CD25high T细胞占CD4+T细胞的比率显著的高于III、IV期(P<0.05);I~II期患者的INF-γ、IL-4、IL-10水平显著的高于III、IV期患者(P<0.05);胰腺癌患者的CD4+CD25high T细胞水平与INF-γ、IL-4、IL-10水平均呈现显著的正相关(r=0.372、r=0.401、r=0.226,P<0.05)。
结论:胰腺癌患者的CD4+CD25high T细胞比率显著的提高,并且与患者的临床分期、免疫功能变化具有一定的关系。 相似文献
11.
Human CD4+ CD25+ T cells regulate CD8+ T-cell activation 总被引:2,自引:0,他引:2
Câmara NO Ng WF Hernandes-Fuentes M Eren E Lechler RI 《Transplantation proceedings》2002,34(7):2858-2860
12.
13.
Acceleration of apoptosis in CD4+CD8+ thymocytes by rapamycin accompanied by increased CD4+CD25+ T cells in the periphery 总被引:11,自引:0,他引:11
BACKGROUND: Rapamycin (Rapa) is an immunosuppressant that is used in patients and animal models to control allograft rejection. Its mechanisms of action are not fully understood. In this article, the authors have investigated the effects of therapeutic doses of Rapa on both thymic and peripheral T-cell populations in the adult rat. METHODS: The therapeutic dosage of Rapa was optimized using cardiac transplantation between LEW and DA rats. Thymic morphology was assessed by hematoxylin-eosin staining. Flow cytometric analysis was performed to analyze T-cell phenotype and apoptosis. T-cell receptor (TCR)-mediated T-cell responsiveness was evaluated by 3[H]-thymidine deoxyribose incorporation. RESULTS: Rapa induced atrophy in the thymus but not in peripheral lymphoid organs. Moreover, fibrosis occurred in thymus that was long-lasting after Rapa withdrawal. In animals treated with Rapa, there was a significant reduction in CD4+CD8+ thymocytes caused by accelerated apoptosis, whereas CD4-CD8-, CD4+CD8-, and CD8+CD4- populations remained unaffected. In contrast, the cellularity of the periphery lymphoid organs was not altered. Within the CD4+ thymocyte population, CD4+CD25+ thymocytes were resistant to Rapa-accelerated apoptosis, and in the periphery, the ratio of CD4+CD25+ to CD4+CD25- T cells was increased. Notably, the peripheral CD4+CD25+ T cells were hyporesponsive to TCR-mediated activation. CONCLUSIONS: The resistance of the peripheral CD4+CD25+ T cells to Rapa treatment might contribute to its immunosuppressive action. The long-term effects of Rapa on thymus atrophy and thymocyte development requires consideration with respect to its clinical application. 相似文献
14.
15.
Yuling H Ruijing X Xiang J Yanping J Lang C Li L Dingping Y Xinti T Jingyi L Zhiqing T Yongyi B Bing X Xinxing W Youxin J Fox DA Lundy SK Guohua D Jinquan T 《Journal of the American Society of Nephrology : JASN》2008,19(11):2130-2139
The source of IgA and the mechanism for deposition of IgA in the mesangium remain unknown for primary IgA nephropathy. Because CD19(+)CD5(+) B cells are important producers of IgA and contribute to several autoimmune diseases, they may play an important role in IgA nephropathy. In this study, flow cytometry, quantitative PCR, and confocal microscopy were used to assess the frequency, distribution, Ig production, CD phenotypes, cytokine production, and sensitivity to apoptosis of CD19(+)CD5(+) B cells in the peripheral blood, peritoneal fluid, and kidney biopsies of 36 patients with primary IgA nephropathy. All patients with IgA nephropathy were significantly more likely to have CD19(+)CD5(+) B cells in the peripheral blood, peritoneal fluid, and kidney biopsies than were five control subjects and 10 patients with active systemic lupus erythematosus. The 33 patients who had IgA nephropathy and responded to treatment demonstrated a significant decrease in CD19(+)CD5(+) B cells in the peripheral blood, peritoneal fluid, and kidney (all P < 0.01). In the three patients who had IgA nephropathy and did not respond to treatment, the frequency of CD19(+)CD5(+) B cells did not change. CD19(+)CD5(+) B cells isolated from patients with untreated IgA nephropathy expressed higher levels of IgA, produced more IFN-gamma, and were more resistant to CD95L-induced apoptosis than cells isolated from control subjects and patients with lupus; these properties reversed with effective treatment of IgA nephropathy. In conclusion, these results strongly suggest that CD19(+)CD5(+) B cells play a prominent role in the pathogenesis of primary IgA nephropathy. 相似文献
16.
BACKGROUND: Injection of neonatal BALB/c mice with semi-allogeneic splenocytes leads to antigen-specific tolerance lasting into adulthood. Tolerant mice accept A/J skin grafts and fail to generate CD8 cytotoxic T lymphocyte (CTL) activity against A/J targets. Anergic CD8 T cells are present in tolerant mice, and CD4 regulatory cells function to maintain CD8 cell anergy. METHODS: Neonatal BALB/c mice were injected with 108 live CAF, splenocytes, and mice were deemed tolerant by accepting A/J grafts over 40 days. CD8 cell proliferation was measured by in vitro incorporation of bromodeoxyuridine coupled with fluorescence-activated cell sorter analysis. Alloantigen-specific cytotoxicity was tested using 51Cr release assays of A/J or third-party targets. RESULTS: We demonstrate that A/J-specific anergic CD8 cells are present in neonatal primed mice that develop tolerance but not in neonatal primed mice that reject A/J skin grafts. Anergic CD8 cells show decreased proliferation and no CTL activity against A/J targets. Addition of interleukin-2 (IL-2) to unfractionated cultures fails to restore CTL activity against A/J targets. However, addition of IL-2 to CD4-depleted cultures restores A/J-specific CD8 CTL activity. Removal of CD4+/CD25+ cells, but not CD4+/CD25- cells, also restores CD8 CTL activity against A/J in the presence, but not the absence, of IL-2. Moreover, when added back into cultures, purified CD4+/CD25+ cells from tolerant mice inhibit the generation of CD8 CTL against A/J targets. CONCLUSION: These data indicate that CD8 anergy is associated with the state of tolerance, and that CD4+CD25+ cells from tolerant mice function to maintain A/J-specific CD8 cell anergy in vitro. 相似文献
17.
目的探讨CD3、CD57、CD20细胞在原发性肝细胞癌(HCC)、癌旁、肝硬化及正常肝组织中的数量及意义.方法HCC 60例,单纯性肝硬化62例,正常肝组织23例,以免疫组化SP法进行CD3、CD57、CD20染色,对阳性细胞数进行定量分析并与临床资料进行相关探讨.结果(1)各组CD3+细胞平均数从高到低为癌旁组织、癌组织、肝硬化组织、正常肝组织(P<0.05);各组CD57+细胞平均数从高到低为癌组织、癌旁组织、正常肝组织、肝硬化组织(P <0.05);各组CD20+细胞平均数从高到低为癌组织、癌旁组织、肝硬化组织、正常肝组织(P <0.01).(2)HCC中CD3+细胞、CD57+细胞、CD20+细胞与组织学分级均无明显关系.(3)HCC中CD57+细胞和CD20+细胞随着临床分期的发展有下降的趋势(P <0.05);HCC中CD3+细胞平均数与临床TNM分期无关.(4)HCC中15月内有转移组的CD57+、CD3+细胞数均少于无转移组(P<0.01).HCC患者15月内有无转移与HCC和癌旁组织中的B细胞分布均无关.结论临床上,随着HCC患者的病情恶化,CD3+、CD57+、CD20+细胞逐渐减少.CD3+、CD57+、CD20+细胞可成为反映机体抗肿瘤特异性细胞免疫状态和生物学行为及判断患者预后的重要指标. 相似文献
18.
19.
20.
目的:探讨血清微环境对小鼠T细胞衰老的调节作用。方法:分别取年老(12~14月龄)及年轻(1.5~2月龄)小鼠各10只,提取其脾脏淋巴细胞及血清,实验分4组。组I为年老鼠T淋巴细胞+10%年轻鼠血清;组II为年老鼠T淋巴细胞+10%年老鼠血清;组III为年轻鼠T淋巴细胞+10%年轻鼠血清;组IV为年轻鼠T淋巴细胞+10%年老鼠血清。培养48h后,经流式细胞术研究CD8+CD28+共表达率差异。结果:组I和组II T细胞表面的CD8+CD28+共表达率分别是(10.84±0.6841)%和(3.18±0.1789)%,组III和组IV T细胞表面的CD8+CD28+共表达分别是(12.5±0.9445)%和(8.36±0.2074)%。各组间对比有统计学差异(P〈0.05)结论:血清微环境具有调节小鼠T细胞衰老的作用,年轻鼠血清能使年老鼠的T细胞表面的CD8+CD28+共表达率提高,年老鼠的血清能使年轻鼠的T细胞表面的CD8+CD28+共表达率降低。 相似文献